PGE2


SMILES CCCCC[C@@H](/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1C/C=C\CCCC(=O)O)O
InChIKey XEYBRNLFEZDVAW-ARSRFYASSA-N

Chemical properties

Hydrogen bond acceptors 4
Hydrogen bond donors 3
Rotatable bonds 12
Molecular weight (Da) 352.2

Drug properties

Molecular type Small molecule
Physiological/Surrogate Endogenous
Approved drug Yes

Database connections

Structure pdb 6AK3 7CX2 7D7M 8GCP 8XOH 8GDB 8GDC

Bioactivities

Receptor Activity Source
GTP Uniprot Species Family Class Type Min Avg Max Database
DP1 PD2R Human Prostanoid A pKi 6.5 6.75 7.0 Guide to Pharmacology
DP2 PD2R2 Human Prostanoid A pKi 5.3 5.3 5.3 Guide to Pharmacology
EP1 PE2R1 Human Prostanoid A pKi 7.3 7.65 8.0 Guide to Pharmacology
EP1 PE2R1 Human Prostanoid A pKd 7.6 7.75 7.9 Guide to Pharmacology
EP2 PE2R2 Human Prostanoid A pKi 7.5 7.9 8.3 Guide to Pharmacology
EP2 PE2R2 Human Prostanoid A pKd 7.7 7.8 7.9 Guide to Pharmacology
EP3 PE2R3 Human Prostanoid A pKd 8.2 8.73 9.5 Guide to Pharmacology
EP3 PE2R3 Human Prostanoid A pKi 9.48 9.48 9.48 Guide to Pharmacology
EP4 PE2R4 Human Prostanoid A pKi 8.1 8.6 9.1 Guide to Pharmacology
EP4 PE2R4 Human Prostanoid A pKd 7.62 8.57 9.52 Guide to Pharmacology
FP PF2R Human Prostanoid A pKi 6.4 6.65 6.9 Guide to Pharmacology
TP TA2R Human Prostanoid A pKi 4.5 4.5 4.5 Guide to Pharmacology
EP1 PE2R1 Mouse Prostanoid A pKi 7.7 7.7 7.7 Guide to Pharmacology
EP3 PE2R3 Rat Prostanoid A pKd 7.82 8.72 9.1 Guide to Pharmacology
EP3 PE2R3 Rat Prostanoid A pKi 9.0 9.0 9.0 Guide to Pharmacology
EP3 PE2R3 Mouse Prostanoid A pKi 9.07 9.07 9.07 Guide to Pharmacology
EP3 PE2R3 Mouse Prostanoid A pKd 8.85 8.85 8.85 Guide to Pharmacology
EP1 PE2R1 Rat Prostanoid A pKi 7.7 7.7 7.7 Guide to Pharmacology
EP1 PE2R1 Rat Prostanoid A pKd 7.3 7.45 7.6 Guide to Pharmacology
FP PF2R Mouse Prostanoid A pKi 7.0 7.0 7.0 Guide to Pharmacology
DP2 PD2R2 Mouse Prostanoid A pKi 5.5 5.5 5.5 Guide to Pharmacology
EP2 PE2R2 Rat Prostanoid A pKi 8.2 8.2 8.2 Guide to Pharmacology
EP2 PE2R2 Rat Prostanoid A pKd 7.8 8.05 8.3 Guide to Pharmacology
EP4 PE2R4 Rat Prostanoid A pKi 9.0 9.0 9.0 Guide to Pharmacology
EP4 PE2R4 Rat Prostanoid A pKd 9.0 9.0 9.0 Guide to Pharmacology
EP4 PE2R4 Mouse Prostanoid A pKd 8.6 8.6 8.6 Guide to Pharmacology
EP4 PE2R4 Mouse Prostanoid A pKi 8.52 8.61 8.7 Guide to Pharmacology
EP2 PE2R2 Mouse Prostanoid A pKi 7.4 7.65 7.9 Guide to Pharmacology
EP2 PE2R2 Mouse Prostanoid A pKd 7.7 7.7 7.7 Guide to Pharmacology
EP4 PE2R4 Mouse Prostanoid A pKi 8.51 8.51 8.51 ChEMBL
EP1 PE2R1 Human Prostanoid A pKi 7.75 7.94 8.04 ChEMBL
EP2 PE2R2 Human Prostanoid A pKi 7.42 8.35 8.99 ChEMBL
EP3 PE2R3 Human Prostanoid A pKi 8.3 8.98 9.48 ChEMBL
EP4 PE2R4 Human Prostanoid A pKi 8.51 9.2 9.96 ChEMBL
EP1 PE2R1 Mouse Prostanoid A pKi 7.7 7.7 7.7 PDSP Ki database
EP3 PE2R3 Mouse Prostanoid A pKi 9.07 9.07 9.07 PDSP Ki database
FP PF2R Mouse Prostanoid A pKi 7.0 7.0 7.0 PDSP Ki database
EP4 PE2R4 Mouse Prostanoid A pKi 8.72 8.72 8.72 PDSP Ki database
EP2 PE2R2 Mouse Prostanoid A pKi 7.92 7.92 7.92 PDSP Ki database
FP PF2R Bovine Prostanoid A pKi 5.47 5.47 5.47 PDSP Ki database
EP3 PE2R3 Bovine Prostanoid A pKi 8.4 8.46 8.52 PDSP Ki database
EP1 PE2R1 Human Prostanoid A pKi 8.04 8.04 8.04 PDSP Ki database
EP3 PE2R3 Human Prostanoid A pKi 9.48 9.48 9.48 PDSP Ki database
EP4 PE2R4 Human Prostanoid A pKi 8.31 8.71 9.1 PDSP Ki database
DP1 PD2R Human Prostanoid A pKi 6.51 6.51 6.51 PDSP Ki database
FP PF2R Human Prostanoid A pKi 6.92 6.92 6.92 PDSP Ki database
IP PI2R Human Prostanoid A pKi 5.0 5.0 5.0 PDSP Ki database
TP TA2R Mouse Prostanoid A pKi 5.0 5.0 5.0 PDSP Ki database
IP PI2R Mouse Prostanoid A pKi 5.0 5.0 5.0 PDSP Ki database
DP1 PD2R Rat Prostanoid A pKi 5.53 5.53 5.53 PDSP Ki database
DP1 PD2R Human Prostanoid A pKi 8.15 8.15 8.15 Drug Central
DP2 PD2R2 Human Prostanoid A pKi 8.28 8.28 8.28 Drug Central
EP1 PE2R1 Human Prostanoid A pKi 8.09 8.09 8.09 Drug Central
EP2 PE2R2 Human Prostanoid A pKi 8.06 8.06 8.06 Drug Central
EP3 PE2R3 Human Prostanoid A pKi 8.02 8.02 8.02 Drug Central
EP4 PE2R4 Human Prostanoid A pKi 8.01 8.01 8.01 Drug Central
FP PF2R Human Prostanoid A pKi 8.16 8.16 8.16 Drug Central
TP TA2R Human Prostanoid A pKi 8.35 8.35 8.35 Drug Central
EP1 PE2R1 Mouse Prostanoid A pKi 8.09 8.09 8.09 Drug Central
EP3 PE2R3 Mouse Prostanoid A pKi 8.08 8.08 8.08 Drug Central
EP1 PE2R1 Rat Prostanoid A pKi 8.11 8.11 8.11 Drug Central
FP PF2R Mouse Prostanoid A pKi 8.15 8.15 8.15 Drug Central
DP2 PD2R2 Mouse Prostanoid A pKi 8.26 8.26 8.26 Drug Central
EP2 PE2R2 Mouse Prostanoid A pKi 8.12 8.12 8.12 Drug Central
EP1 PE2R1 Mouse Prostanoid A pKi 8.22 8.22 8.22 ChEMBL
EP3 PE2R3 Mouse Prostanoid A pKi 8.3 8.3 8.3 ChEMBL
EP4 PE2R4 Mouse Prostanoid A pKi 8.07 8.07 8.07 Drug Central
EP2 PE2R2 Mouse Prostanoid A pKi 7.66 7.66 7.66 ChEMBL
Receptor Activity Source
GTP Uniprot Species Family Class Type Min Avg Max Database
EP4 PE2R4 Human Prostanoid A pEC50 6.05 6.05 6.05 Guide to Pharmacology
EP3 PE2R3 Rat Prostanoid A pEC50 9.39 9.39 9.39 Guide to Pharmacology
EP2 PE2R2 Rat Prostanoid A pIC50 8.28 8.28 8.28 ChEMBL
EP2 PE2R2 Rat Prostanoid A pEC50 7.72 8.71 9.7 ChEMBL
EP4 PE2R4 Rat Prostanoid A pIC50 8.68 8.68 8.68 ChEMBL
EP4 PE2R4 Rat Prostanoid A pEC50 8.46 8.8 9.15 ChEMBL
IP PI2R Human Prostanoid A pIC50 6.58 6.58 6.58 ChEMBL
IP PI2R Human Prostanoid A pEC50 6.46 6.46 6.46 ChEMBL
EP1 PE2R1 Human Prostanoid A pIC50 8.96 8.96 8.96 ChEMBL
EP1 PE2R1 Human Prostanoid A pEC50 8.43 8.43 8.43 ChEMBL
EP2 PE2R2 Human Prostanoid A pIC50 7.42 8.36 8.66 ChEMBL
EP2 PE2R2 Human Prostanoid A pEC50 6.46 7.67 8.72 ChEMBL
EP3 PE2R3 Human Prostanoid A pEC50 8.6 8.6 8.6 ChEMBL
EP3 PE2R3 Human Prostanoid A pIC50 9.03 9.03 9.03 ChEMBL
EP4 PE2R4 Human Prostanoid A pEC50 8.12 9.02 10.7 ChEMBL
EP4 PE2R4 Human Prostanoid A pIC50 8.0 8.78 9.35 ChEMBL
EP3 PE2R3 Rat Prostanoid A pEC50 8.03 8.03 8.03 Drug Central
EP2 PE2R2 Rat Prostanoid A pIC50 8.08 8.08 8.08 Drug Central
EP4 PE2R4 Rat Prostanoid A pIC50 8.06 8.06 8.06 Drug Central
TSH TSHR Human Glycoprotein hormone A Potency 8.0 8.0 8.0 ChEMBL
FP PF2R Human Prostanoid A pEC50 6.6 6.6 6.6 ChEMBL
IP PI2R Human Prostanoid A pIC50 8.18 8.18 8.18 Drug Central